A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias-Reference-Cited by-同舟云学术

A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias

Published:2014-05-22 Issue:21 Volume:123 Page:3296-3304
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Dubrovsky Leonid¹²^ORCID,Pankov Dmitry¹³,Brea Elliott Joseph¹⁴,Dao Tao¹,Scott Andrew¹,Yan Su⁵,O’Reilly Richard J¹²³,Liu Cheng⁵,Scheinberg David A.¹⁴

Affiliation:

1. Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, New York, NY;

2. Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY;

3. Immunology Program, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY;

4. Weill Cornell Medical College, New York, NY; and

5. Eureka Therapeutics, Emeryville, CA

Abstract

Key Points This study shows the effective anticancer activity of a T-cell receptor mimic antibody targeting WT1 in resistant human Ph+ ALL. In combination with tyrosine kinase inhibitors, ESKM can result in cure of Ph+ ALL in murine models.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/21/3296/1377629/3296.pdf

Reference41 articles.

1. The genomic organization and expression of the WT1 gene.;Gessler;Genomics,1992

2. Alternative splicing and genomic structure of the Wilms tumor gene WT1.;Haber;Proc Natl Acad Sci USA,1991

3. Expression, purification, and characterization of the 4 zinc finger region of human tumor suppressor WT1.;Nurmemmedov;Protein Expr Purif,2006

4. The candidate Wilms’ tumour gene is involved in genitourinary development.;Pritchard-Jones;Nature,1990

5. The Wilms’ tumor gene product WT1 activates or suppresses transcription through separate functional domains.;Wang;J Biol Chem,1993

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polymeric Amorphous Solid Dispersions of Dasatinib: Formulation and Ecotoxicological Assessment;Pharmaceutics;2024-04-18

2. Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor–positive Breast Cancer;Cancer Research Communications;2024-02-22

3. Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable;Clinical Cancer Research;2023-11-22

4. Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC/CD3 T cell engagers;Frontiers in Immunology;2023-11-10

5. PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity;Journal for ImmunoTherapy of Cancer;2023-10